Provider Briefing: Sotyktu Availability in 2026

Sotyktu (Deucravacitinib) — the first-in-class selective TYK2 inhibitor for moderate-to-severe plaque psoriasis — continues to face practical access challenges in 2026. While the drug is not listed on the FDA's official shortage database, many of your patients are reporting difficulty filling prescriptions at retail pharmacies.

This article provides a concise overview of the current supply landscape, prescribing considerations, cost and insurance dynamics, and tools that can help your practice streamline access for patients.

Timeline: Sotyktu's Market Journey

Understanding how we got here provides important context:

• September 2022: FDA approves Deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
• Late 2022–2023: BMS launches with a specialty pharmacy distribution model, limiting retail availability from the outset.
• 2023–2024: Prescriber adoption grows steadily within dermatology. Payer formularies begin to include Sotyktu, though with significant access restrictions (prior authorization, step therapy).
• 2025–2026: Patient awareness increases. Reports of difficulty finding the drug at retail pharmacies become common, driven by the specialty distribution model rather than a supply disruption.

Prescribing Implications

Several factors are worth considering when prescribing Sotyktu in the current environment:

Distribution Model

Sotyktu is primarily distributed through specialty pharmacies. If you send the prescription to a standard retail pharmacy (CVS, Walgreens, etc.), the patient will likely be told it's not in stock. Best practice: Route prescriptions directly to a specialty pharmacy or use your practice's specialty pharmacy liaison.

Prior Authorization Requirements

The majority of commercial and Medicare Part D plans require prior authorization for Sotyktu. Common requirements include:

• Confirmed diagnosis of moderate-to-severe plaque psoriasis
• Documentation of body surface area (BSA) involvement
• Failure of at least one prior systemic therapy (e.g., Methotrexate, phototherapy, or a biologic) — step therapy
• Prescriber must be a dermatologist (some plans)

Prior auth turnaround varies from 2–14 business days. Peer-to-peer reviews may be required for denials.

No Boxed Warning Advantage

Unlike JAK inhibitors (Xeljanz, Rinvoq, Cibinqo), Sotyktu does not carry a boxed warning for major adverse cardiovascular events (MACE), malignancies, or venous thromboembolism. This differentiation is clinically meaningful and may simplify the risk-benefit conversation with patients, particularly those concerned about JAK inhibitor safety signals.

Current Availability Picture

As of early 2026:

• FDA shortage status: Not listed
• Manufacturing: BMS reports no supply disruptions
• Retail pharmacy stock: Limited. Most chain pharmacies do not routinely carry Sotyktu.
• Specialty pharmacy stock: Generally available through BMS-affiliated specialty pharmacy networks

The disconnect between "no shortage" and "patients can't find it" is driven entirely by the distribution model. Patient-facing education on this distinction can reduce frustration — direct them to our patient explainer on Sotyktu availability.

Cost and Access

Pricing for Sotyktu remains high:

• Wholesale acquisition cost (WAC): ~$2,000–$2,400/month
• Annual cost: ~$72,000–$80,000
• Generic availability: None. Patent protection expected through the late 2030s.

Insurance Coverage

Most commercial plans and Medicare Part D include Sotyktu on their formularies, typically at a specialty tier with:

• Prior authorization required
• Step therapy (fail-first) required
• Quantity limits (30 tablets per fill)

Financial Assistance for Patients

• BMS Sotyktu Savings Card: Commercially insured patients may pay as little as $0/month
• BMS Patient Assistance Foundation: Free medication for qualifying uninsured/underinsured patients
• Third-party resources: NeedyMeds, RxAssist, and coupon platforms (SingleCare, GoodRx)

For details, see our patient savings guide or the provider cost guide.

Tools and Resources

Several tools can help your practice manage Sotyktu access more efficiently:

Medfinder for Providers

Medfinder offers real-time pharmacy stock checking for specialty medications including Sotyktu. You and your staff can search by zip code to identify pharmacies with current inventory, reducing the back-and-forth with patients who can't locate the drug.

BMS Access Support

BMS provides a dedicated access support team that can assist with:

• Locating specialty pharmacies with stock
• Navigating prior authorization
• Connecting patients with financial assistance

Electronic Prior Authorization (ePA)

If your EHR supports electronic prior authorization, use it to streamline approvals. Many payers now accept ePA for Sotyktu, reducing turnaround time from weeks to days.

Looking Ahead

The TYK2 inhibitor class is expanding. Additional TYK2 inhibitors are in late-stage clinical development from other manufacturers, which may increase competition and improve access over time. Deucravacitinib is also being studied in psoriatic arthritis and systemic lupus erythematosus, which — if approved — could broaden both the prescriber base and distribution footprint.

In the meantime, proactive management of the prescription pathway — routing to specialty pharmacies, front-loading prior auth, and leveraging tools like Medfinder — remains the most effective strategy for ensuring patients can access Sotyktu without interruption.

Final Thoughts

Sotyktu represents an important advance in oral psoriasis therapy, offering a differentiated safety profile compared to JAK inhibitors. The access challenges in 2026 are real but manageable with the right workflow. Educate your patients about specialty pharmacy access, proactively manage prior authorizations, and use Medfinder for providers to quickly locate stock when needed.

For patient-facing materials you can share, see our patient guide on finding Sotyktu and alternatives guide.